Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Pierre J. LeBel who wrote (739)	3/6/1998 11:54:00 PM
From: READE SMITH	Read Replies (1) \| Respond to of 14101

We're all waiting for news from the U.K or Canada's Health Protection Branch -- in the meantime DMX seems to have found a new base resistance at $3.50 (it was just below $3). This is partially due to the recent independent study which proved Pennsaid's effectiveness with no significant side effects. There is nothing but time now (a few months?) between us and revenues from North American and British sales. Next step -- we'll announce a Pennsaid marketing partner and a new double-blind WF-10 study then shoot up over $4 again -- how boring -- this interminable wait for the " big one".